ライフサイエンスコーパス: , with no difference

コーパス検索結果 (right1)

通し番号をクリックするとPubMedの該当ページを表示します

1 Attrition was 13.9%, with no difference across groups.

2 1%), constitutional (3.5% to 9.5%), and cardiac (4.5% to 6%), with no difference among the arms.

3 22.7 [13.1-56.2] compared with 3.80 [1.15-11.5], p = 0.0004), with no difference between cART-naive and VS patients (p =

4 2 during extended buprenorphine-naloxone treatment (week 12), with no difference between counseling conditions.

5 survival rate improved after the advent of cART (38% vs 69%), with no difference between EORTC-IA and HIV-related IA (haz

6 remission [CR], 60%; CR with incomplete recovery [CRi], 9%), with no difference between GO (70%) and no GO (68%) arms.

7 The overall biliary complication rate was 22.5% (n = 42), with no difference between groups (P = 0.35).

8 -3.35+/-0.5 pA/pF versus -9.13+/-1.0 pA/pF in the controls), with no difference between groups in the voltage dependence

9 6.9%]; vigorous intensity/moderate duration = 18.9% [16.9%]), with no difference between groups.

10 III batches positive; six of six factor IX batches positive), with no difference between renumerated and non-renumerated

11 d possible stent thrombosis appeared in 279 patients (13.3%), with no difference between stent types and with a steady an

12 ncidence of post-operative surgical complications was 52.3 %, with no difference between stented and non-stented patients

13 cted brother, the lifetime FRR was 5.88 (95% CI: 4.70, 7.36), with no difference between subtypes.

14 as many TAC-HI-P (63%) as TAC-LO-P patients (32%, P < 0.05), with no difference between TAC-HI-P and CsA (86%, NS).

15 Overall hospital mortality was 7.3%, with no difference between the 2 types of valve prostheses

16 The overall biliary complication rate was 25%, with no difference between the 237 patients who received tr

17 cose phases than in the aspartame phase (P < 0.003 for each), with no difference between the fructose and glucose phases

18 0.001, two-way ANOVA) and SC-236-treated groups (P < 0.0001), with no difference between these treatments.

19 hip and the spine after 12 months of treatment (P = 0.0002), with no difference between treatment groups.

20 T. vaginalis detection rate in males was 6.6%, with no difference between urethral and urine T. vaginalis

21 One-year survival was 67.8%, with no difference by treatment arm (67.3% vs. 68.3% for in

22 er the first administration of ticagrelor (P<0.001 for both), with no difference in aggregation between groups (multiple

23 the active and placebo groups, respectively (nonsignificant), with no difference in AUC analysis for measured erythema in

24 provisional group (31.6% vs. 38.6%, p=0.002 for superiority), with no difference in binary restenosis rates (diameter ste

25 ges within 24 hours increased from 20.0% to 38.4% (P < .001), with no difference in ED bronchiolitis admission or ED revi

26 Ees/Ep: -26 +/- 47% vs. +20 +/- 47% for controls) (p < 0.01), with no difference in Ees/Ea.

27 : 0.04, 0.71; BMI z score difference: 0.35; 95% CI: 0, 0.69), with no difference in linear growth (z score difference: 0.

28 .06) and renal failure (OR, 1.30; 95% CI, 0.98-1.72; P=0.06), with no difference in major bleeding (OR, 1.47; 95% CI, 0.3

29 f nonreclassified patients (FFR concordant with angiography), with no difference in major cardiovascular event (8.0% vers

30 ds ratio, 0.70; 95% confidence interval, 0.52-0.92; P=0.012), with no difference in mortality or myocardial infarction.

31 as reduced in FH+ (7.1 +/- 0.9% vs. 11.7 +/- 1.6%, p < 0.02), with no difference in nitroglycerin-induced endothelium-ind

32 was all-cause mortality (1.3% vs. 3.2%; HR: 0.39; p = 0.006), with no difference in NSTEACS patients.

33 am (14 +/- 2.4 vs. 9.5 +/- 1.6 units.mg protein(1), p < .01), with no difference in protein expression of manganese super

34 of 51 patients (38%); LCB, 20 of 50 patients (40%; P = .48), with no difference in RECIST response: BB, 5.9% versus LCB,

35 rienced readers, specificity increased to 94% and PPV to 98%, with no difference in sensitivity and NPV.

36 ference, 0.37 days; 95% confidence interval [CI], 0.06-0.68), with no difference in severity of menstrual flow.

37 ol kg-1 h-1, LP + G; 51.7 +/- 5.5 micromol kg-1 h-1, LP + W), with no difference in skeletal muscle branched-chain 2-oxo

38 01), and vascular complications (1.0% versus 2.5%; P<0.0001), with no difference in survival.

39 = .004, respectively) and more pain on injection (P = .001), with no difference in the rates of fever, infection, or hem

40 ratio, 0.49; 95% confidence interval, 0.30 to 0.81; P=0.004), with no difference in the rates of hemorrhagic stroke betwe

41 more subjects on tadalafil compared with placebo (p < 0.05), with no difference in the response to nitroglycerin at 48,

42 1) and vice versa for those born in 1968 or later (P < .001), with no difference in those born between 1957 and 1967 (P =

43 small tumor confined to the liver (657 of 1,597 cases, 41%), with no difference in treatment by hepatic comorbidity stat

44 higher proportion of early HCC (70.2% vs. 40.0%; P = 0.009), with no difference in tumor stage between ultrasound- and A

45 stion of whole eggs (68% +/- 1%) and egg whites (66% +/- 2%), with no difference in whole-body net leucine balance (P = 0

46 The median baseline exercise test score was 3.0 (range, 0-4), with no difference noted between the baseline and placebo (

47 and maximal stroke volume increased 16% (104 versus 121 mL), with no difference observed in maximal cardiac output (20.0

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。